Lenalidomide and vorinostat maintenance after autologous transplant in multiple myeloma

British Journal of Haematology

Volumn 171, Issue 1, 2015, Pages 74-83

  Sborov, Douglas W ^a   Benson, Don M ^a   Williams, Nita ^a   Huang, Ying ^a   Bowers, Mindy A ^b   Humphries, Kristina ^b   Efebera, Yvonne ^a   Devine, Steven ^a   Hofmeister, Craig C ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Autologous transplant; Deacetylase inhibition; Immunomodulatory agent; Myeloma

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BORTEZOMIB; CREATININE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; LENALIDOMIDE; MELPHALAN; POMALIDOMIDE; PREDNISONE; STEROID; VORINOSTAT; ANTINEOPLASTIC AGENT; HYDROXAMIC ACID; THALIDOMIDE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER GROWTH; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOPENIA; DIARRHEA; DRUG DOSE ESCALATION; DRUG MEGADOSE; DRUG TOLERABILITY; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; HYPOKALEMIA; LEUKOPENIA; LYMPHOCYTOPENIA; LYMPHOMA; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RASH; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING; AGED; ANALOGS AND DERIVATIVES; AUTOGRAFT; CLINICAL TRIAL; DISEASE FREE SURVIVAL; MAINTENANCE CHEMOTHERAPY; MIDDLE AGED; MORTALITY; ORAL DRUG ADMINISTRATION; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; SURVIVAL RATE;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AUTOGRAFTS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; HYDROXAMIC ACIDS; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; SURVIVAL RATE; THALIDOMIDE;

EID: 84941748780     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13527     Document Type: Article

References (33)

1. Attal, M., Lauwers-Cances, V., Marit, G., Caillot, D., Moreau, P., Facon, T., Stoppa, A.M., Hulin, C., Benboubker, L., Garderet, L., Decaux, O., Leyvraz, S., Vekemans, M.C., Voillat, L., Michallet, M., Pegourie, B., Dumontet, C., Roussel, M., Leleu, X., Mathiot, C., Payen, C., Avet-Loiseau, H. & Harousseau, J.L. (2012) Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. New England Journal of Medicine, 366, 1782-1791.
2. Badros, A., Burger, A.M., Philip, S., Niesvizky, R., Kolla, S.S., Goloubeva, O., Harris, C., Zwiebel, J., Wright, J.J., Espinoza-Delgado, I., Baer, M.R., Holleran, J.L., Egorin, M.J. & Grant, S. (2009) Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma. Clinical Cancer Research, 15, 5250-5257.
3. Campbell, R.A., Sanchez, E., Steinberg, J., Shalitin, D., Li, Z.W., Chen, H. & Berenson, J.R. (2010) Vorinostat enhances the antimyeloma effects of melphalan and bortezomib. European Journal of Haematology, 84, 201-211.
4. Carbone, E., Neri, P., Mesuraca, M., Fulciniti, M.T., Otsuki, T., Pende, D., Groh, V., Spies, T., Pollio, G., Cosman, D., Catalano, L., Tassone, P., Rotoli, B. & Venuta, S. (2005) HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells. Blood, 105, 251-258.
5. Cella, D.F., Tulsky, D.S., Gray, G., Sarafian, B., Linn, E., Bonomi, A., Silberman, M., Yellen, S.B., Winicour, P., Brannon, J., Eckberg, K., Lloyd, S., Puri, S., Blendowski, C., Goodman, M., Bornicle, M., Stewart, I., McHale, M., Bonomi, P., Kaplan, E., Taylor, S., Thomas, C.R. & Harris, J. (1993) The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. Journal of Clinical Oncology, 11, 570-579.
6. Davies, F.E., Raje, N., Hideshima, T., Lentzsch, S., Young, G., Tai, Y.T., Lin, B., Podar, K., Gupta, D., Chauhan, D., Treon, S.P., Richardson, P.G., Schlossman, R.L., Morgan, G.J., Muller, G.W., Stirling, D.I. & Anderson, K.C. (2001) Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood, 98, 210-216.
7. Dimopoulos, M., Siegel, D.S., Lonial, S., Qi, J., Hajek, R., Facon, T., Rosinol, L., Williams, C., Blacklock, H., Goldschmidt, H., Hungria, V., Spencer, A., Palumbo, A., Graef, T., Eid, J.E., Houp, J., Sun, L., Vuocolo, S. & Anderson, K.C. (2013) Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study. The Lancet Oncology, 14, 1129-1140.
8. Duvic, M., Kim, Y.H., Kuzel, T.M., Pacheco, T.R., Foss, F.M., Parker, S., Frankel, S.R., Chen, C., Ricker, J.L., Arduino, J.M., Randolph, S., Richon, V.M. & Olsen, E.A. (2006) Vorinostat (suberoylanilide hydroxamic acid, SAHA) provides prolonged clinical benefit to advanced cutaneous T-cell lymphoma patients: updated results of the phase IIb multicenter clinical trial. Blood (ASH Annual Meeting Abstracts), 108, 399.
9. Duvic, M., Talpur, R., Ni, X., Zhang, C., Hazarika, P., Kelly, C., Chiao, J.H., Reilly, J.F., Ricker, J.L., Richon, V.M. & Frankel, S.R. (2007) Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood, 109, 31-39.
10. Gialitakis, M., Kretsovali, A., Spilianakis, C., Kravariti, L., Mages, J., Hoffmann, R., Hatzopoulos, A.K. & Papamatheakis, J. (2006) Coordinated changes of histone modifications and HDAC mobilization regulate the induction of MHC class II genes by Trichostatin A. Nucleic Acids Research, 34, 765-772.
11. Hayashi, T., Hideshima, T., Akiyama, M., Podar, K., Yasui, H., Raje, N., Kumar, S., Chauhan, D., Treon, S.P., Richardson, P. & Anderson, K.C. (2005) Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. British Journal of Haematology, 128, 192-203.
12. Herman, J.G. & Baylin, S.B. (2003) Gene silencing in cancer in association with promoter hypermethylation. New England Journal of Medicine, 349, 2042-2054.
13. Irwin, M., Artin, K.H. & Oxman, M.N. (1999) Screening for depression in the older adult: criterion validity of the 10-item Center for Epidemiological Studies Depression Scale (CES-D). Archives of Internal Medicine, 159, 1701-1704.
14. Kaufman, J.L., Shah, J.J., Laubach, J.P., Heffner, L., Francis, D., Harvey, R.D., Lewis, C., Tighiouart, M., Richardson, P., Orlowski, R.Z. & Lonial, S. (2010) Lenalidomide, bortezomib, and dexamethasone (RVD) in combination with vorinostat as front-line therapy for patients with multiple myeloma (MM): initial results of a phase 1 study. Blood (ASH Annual Meeting Abstracts), 116, 3034.
15. Kikuchi, J., Wada, T., Shimizu, R., Izumi, T., Akutsu, M., Mitsunaga, K., Noborio-Hatano, K., Nobuyoshi, M., Ozawa, K., Kano, Y. & Furukawa, Y. (2010) Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma. Blood, 116, 406-417.
16. Leoni, F., Zaliani, A., Bertolini, G., Porro, G., Pagani, P., Pozzi, P., Dona, G., Fossati, G., Sozzani, S., Azam, T., Bufler, P., Fantuzzi, G., Goncharov, I., Kim, S.H., Pomerantz, B.J., Reznikov, L.L., Siegmund, B., Dinarello, C.A. & Mascagni, P. (2002) The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines. Proceedings of the National Academy of Sciences of the United States of America, 99, 2995-3000.
17. McCarthy, P.L., Owzar, K., Hofmeister, C.C., Hurd, D.D., Hassoun, H., Richardson, P.G., Giralt, S., Stadtmauer, E.A., Weisdorf, D.J., Vij, R., Moreb, J.S., Callander, N.S., Van Besien, K., Gentile, T., Isola, L., Maziarz, R.T., Gabriel, D.A., Bashey, A., Landau, H., Martin, T., Qazilbash, M.H., Levitan, D., McClune, B., Schlossman, R., Hars, V., Postiglione, J., Jiang, C., Bennett, E., Barry, S., Bressler, L., Kelly, M., Seiler, M., Rosenbaum, C., Hari, P., Pasquini, M.C., Horowitz, M.M., Shea, T.C., Devine, S.M., Anderson, K.C. & Linker, C. (2012) Lenalidomide after stem-cell transplantation for multiple myeloma. New England Journal of Medicine, 366, 1770-1781.
18. Mendoza, T.R., Wang, X.S., Cleeland, C.S., Morrissey, M., Johnson, B.A., Wendt, J.K. & Huber, S.L. (1999) The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory. Cancer, 85, 1186-1196.
19. Minami, J., Suzuki, R., Mazitschek, R., Gorgun, G., Ghosh, B., Cirstea, D., Hu, Y., Mimura, N., Ohguchi, H., Cottini, F., Jakubikova, J., Munshi, N.C., Haggarty, S.J., Richardson, P.G., Hideshima, T. & Anderson, K.C. (2014) Histone deacetylase 3 as a novel therapeutic target in multiple myeloma. Leukemia, 28, 680-689.
20. Mitsiades, C.S., Mitsiades, N.S., McMullan, C.J., Poulaki, V., Shringarpure, R., Hideshima, T., Akiyama, M., Chauhan, D., Munshi, N., Gu, X., Bailey, C., Joseph, M., Libermann, T.A., Richon, V.M., Marks, P.A. & Anderson, K.C. (2004) Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proceedings of the National Academy of Sciences of the United States of America, 101, 540-545.
21. Nooka, A.K., Kaufman, J.L., Muppidi, S., Langston, A., Heffner, L.T., Gleason, C., Casbourne, D., Saxe, D., Boise, L.H. & Lonial, S. (2014) Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients. Leukemia, 28, 690-693.
22. Pei, X.Y., Dai, Y. & Grant, S. (2004) Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clinical Cancer Research, 10, 3839-3852.
23. Porrata, L.F., Inwards, D.J., Ansell, S.M., Micallef, I.N., Johnston, P.B., Gastineau, D.A., Litzow, M.R., Winters, J.L. & Markovic, S.N. (2008) Early lymphocyte recovery predicts superior survival after autologous stem cell transplantation in non-Hodgkin lymphoma: a prospective study. Biology of Blood and Marrow Transplantation, 14, 807-816.
24. Quach, H., Ritchie, D., Stewart, A.K., Neeson, P., Harrison, S., Smyth, M.J. & Prince, H.M. (2010) Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia, 24, 22-32.
25. Richardson, P., Mitsiades, C., Colson, K., Reilly, E., McBride, L., Chiao, J., Sun, L., Ricker, J., Rizvi, S., Oerth, C., Atkins, B., Fearen, I., Anderson, K. & Siegel, D. (2008) Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. Leukaemia & Lymphoma, 49, 502-507.
26. Siegel, D.S., McBride, L., Bilotti, E., Schmidt, L., Gao, Z., Tufail, M., Lendvai, N., McNeill, A., Donadio, K., Olivo, K., Bednarz, U., Graef, T. & Vesole, D.H. (2010) Vorinostat overcomes lenalidomide-dexamethasone and lenalidomide-bortezomib-dexamethasone resistance in relapsed/refractory multiple myeloma. Blood (ASH Annual Meeting Abstracts), 116, 3065.
27. Siegel, D.S., Dimopoulos, M.A., Yoon, S.-S., Laubach, J.P., Kaufman, J.L., Goldschmidt, H., Reece, D.E., Leleu, X., Durrant, S., Offner, F.C., Cavo, M., Nagler, A., Jagannath, S., Graef, T., Houp, J., Sun, L., Howe, J., Wear, S.M. & Anderson, K.C. (2011) Vantage 095: vorinostat in combination with bortezomib in salvage multiple myeloma patients: final study results of a global phase 2b trial. Blood (ASH Annual Meeting Abstracts), 118, 480.
28. Siegel, D.S., Richardson, P., Dimopoulos, M., Moreau, P., Mitsiades, C., Weber, D., Houp, J., Gause, C., Vuocolo, S., Eid, J., Graef, T. & Anderson, K.C. (2014) Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma. Blood Cancer Journal, 4, e182.
29. Skov, S., Pedersen, M.T., Andresen, L., Straten, P.T., Woetmann, A. & Odum, N. (2005) Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B. Cancer Research, 65, 11136-11145.
30. Vogl, D.T., Hari, P.N., Jagannath, S., Jones, S.S., Supko, J.G., Leone, G., Wheeler, C., Orlowski, R.Z., Richardson, P.G. & Lonial, S. (2013) ACY-1215, a selective histone deacetylase (HDAC) 6 inhibitor: interim results of combination therapy with bortezomib in patients with multiple myeloma (MM). Blood (ASH Annual Meeting Abstracts), 122, 759.
31. Vorhees, P., Bensinger, W.I., Berdeja, J., Supko, J.G., Richardson, P.G., Jones, S.S., Patrick, G., Wheeler, C. & Raje, N. (2013) ACY-1215, a selective histone deacetylase (HDAC) 6 inhibitor, in combination with lenalidomide and dexamethasone (dex), is well tolerated without dose limiting toxicity (DLT) in patients (Pts) with multiple myeloma (MM) at doses demonstrating biologic activity: interim results of a phase 1b trial. Blood (ASH Annual Meeting Abstracts), 122, 3190.
32. Weber, D.M., Graef, T., Hussein, M., Sobecks, R.M., Schiller, G.J., Lupinacci, L., Hardwick, J.S. & Jagannath, S. (2012) Phase I trial of vorinostat combined with bortezomib for the treatment of relapsing and/or refractory multiple myeloma. Clinical Lymphoma, Myeloma and Leukemia, 12, 319-324.
33. Wider, D., Keller, K., Groß, B., Reinhardt, H., Jakobs, D., Moeller, M.-D., Burbeck, M., Pantic, M., May, A., Jung, M., Waesch, R. & Engelhardt, M. (2013) Vorinostat (V) in combination with bortezomib (B), doxorubicin (D) and dexamethasone (D) (VBDD) in patients with refractory or relapsed multiple myeloma: an interim phase I/II analysis. Onkologie, 36, 152.